VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
OriCell Therapeutics' GPC3 CAR-T Ori-C101 Achieves 66.7% ORR in Advanced Liver Cancer, Signaling Best-in-Class Potential
OriCell Therapeutics' GPC3 CAR-T Ori-C101 Achieves 66.7% ORR in Advanced Liver Cancer, Signaling Best-in-Class Potential
Jun 01, 2026 10:41 CST Updated 12:50
Share:
